Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
- PMID: 32281055
- PMCID: PMC7152511
- DOI: 10.1007/s40256-020-00406-0
Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
Abstract
There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
Conflict of interest statement
Chia Siang Kow, Syed Tabish Razi Zaidi, and Syed Shahzad Hasan declare that they have no potential conflicts of interest that might be relevant to this manuscript.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources